Delayed cardiac dysrhythmias after fingolimod administration
Jamie M Rosini1, Suraj Rajasimhan1, Shawn E Fellows1
1Department of Pharmacy, Christiana Care Health System, 4755 Ogletown-Stanton Road, Newark, DE, 19718 USA.
Fingolimod, used for multiple sclerosis, can cause heart rhythm issues like Mobitz Type I AV block and junctional tachycardia. Extended cardiac monitoring is recommended after fingolimod administration due to potential cardiac side effects.
Area of Science:
- Neurology
- Cardiology
Background:
- Fingolimod is a sphingosine-1-phosphate receptor modulator used to treat relapsing-remitting multiple sclerosis.
- Cardiac adverse events, including bradycardia and atrioventricular (AV) block, are known side effects of fingolimod therapy.
More Related Videos
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dysrhythmias VII: Nursing Management of Dysrhythmias
Dysrhythmias V: Evaluating Dysrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
